Dutch State to sell share capital of Intravacc BV

Two years after the establishment of the private company Intravacc BV (Bilthoven, The Netherlands), the sale of the former Netherlands Vaccine Institute including all technology platforms, product portfolio, intellectual property, and a highly skilled workforce of around 100 professionals will be conducted through a controlled auction process.

Production had already been outsourced in 2012. After all the Dutch Health Ministery concluded that there was not enough added value to uphold R&D activities – the sale of the former state-ownded institute was just halted by the corona pandemic.

Intravacc is an independent CDMO (contract development and manufacturing organization) for infectious diseases and therapeutic vaccines, offering process development, pre-clinical and manufacturing services from proof-of-concept to Phase I/II. As a part of the former Netherlands Vaccine Institute, the Company has long-standing expertise and know-how in vaccine development and optimisation. Intravacc has
developed, out-licensed and transferred its technology related to vaccines against polio, measles, diphtheria, Hib and influenza around the world.

The auction process will be led by EY Strategy and Transactions,